• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2018 - 2019年国防部受益人群中呼吸道病原体监测趋势及流感疫苗有效性评估

Respiratory pathogen surveillance trends and influenza vaccine effectiveness estimates for the 2018-2019 season among Department of Defense beneficiaries.

作者信息

Kersellius Geeta D, Gruner William E, Fries Anthony C, DeMarcus Laurie S, Robbins Anthony S

出版信息

MSMR. 2020 Jan;27(1):17-23.

PMID:32023072
Abstract

This report primarily focuses on the data collected and analyzed from the worldwide network of sentinel military treatment facilities chosen to participate in the Department of Defense Global Respiratory Pathogen Surveillance (DoDGRS) program. Sites that participated in the 2018-2019 DoDGRS program submitted 24,320 respiratory specimens for diagnostic testing. Clinical results showed a total of 5,968 positive influenza cases. In the beginning of the season, starting in surveillance week 48, influenza A(H1N1)pdm09 was the predominant subtype. The predominant subtype switched to influenza A(H3N2) beginning in week 6 and continued through the end of the season. Influenza B virus detection was less common during the surveillance period (i.e., 1% of total submitted specimens and 5% of total influenza detected). In addition to routine surveillance, the DoDGRS program also conducts vaccine effectiveness (VE) studies twice per year to determine interim and end of season estimates. Overall, the adjusted end of season VE for all dependents regardless of influenza type was 30% (95% CI: 22%-38%).

摘要

本报告主要关注从被选参与国防部全球呼吸道病原体监测(DoDGRS)项目的全球哨点军事治疗机构网络收集和分析的数据。参与2018 - 2019年DoDGRS项目的站点提交了24320份呼吸道标本进行诊断检测。临床结果显示共有5968例流感阳性病例。在季节开始时,从监测第48周起,甲型(H1N1)pdm09流感是主要亚型。从第6周开始,主要亚型转变为甲型(H3N2)流感,并持续到季节结束。在监测期间,乙型流感病毒检测较少见(即占提交标本总数的1%,占检测到的流感总数的5%)。除常规监测外,DoDGRS项目每年还进行两次疫苗效力(VE)研究,以确定季节中期和末期的评估结果。总体而言,所有受抚养者无论流感类型的调整后季节末期疫苗效力为30%(95%置信区间:22% - 38%)。

相似文献

1
Respiratory pathogen surveillance trends and influenza vaccine effectiveness estimates for the 2018-2019 season among Department of Defense beneficiaries.2018 - 2019年国防部受益人群中呼吸道病原体监测趋势及流感疫苗有效性评估
MSMR. 2020 Jan;27(1):17-23.
2
Influenza Surveillance Trends and Influenza Vaccine Effectiveness Among Department of Defense Beneficiaries During the 2019-2020 Influenza Season.2019-2020 流感季期间,国防部受益人群中的流感监测趋势和流感疫苗有效性。
MSMR. 2021 Mar;28(3):2-8.
3
Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the I-MOVE multicentre case-control study, influenza season 2012/13.在一个同时流行三种流感病毒型/亚型的季节里,对欧洲流感疫苗有效性的评估:I-MOVE 多中心病例对照研究,2012/13 年流感季节。
Euro Surveill. 2014 Feb 13;19(6):20701. doi: 10.2807/1560-7917.es2014.19.6.20701.
4
Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15.2014/15 年在欧洲,I-MOVE 多中心病例对照研究中,在甲型 H1N1pdm09、乙型和漂移型甲型 H3N2 流感共同流行的季节,初级保健患者中预防实验室确诊流感的疫苗效力。
Euro Surveill. 2016;21(7):pii=30139. doi: 10.2807/1560-7917.ES.2016.21.7.30139.
5
The DoD Global, Laboratory-based, Influenza Surveillance Program: summary for the 2013-2014 influenza season.美国国防部全球实验室流感监测计划:2013 - 2014年流感季节总结
MSMR. 2016 Mar;23(3):2-5.
6
Interim Estimates of 2019-20 Seasonal Influenza Vaccine Effectiveness - United States, February 2020.2019-20 季节性流感疫苗效力的临时估计-美国,2020 年 2 月。
MMWR Morb Mortal Wkly Rep. 2020 Feb 21;69(7):177-182. doi: 10.15585/mmwr.mm6907a1.
7
The European I-MOVE Multicentre 2013-2014 Case-Control Study. Homogeneous moderate influenza vaccine effectiveness against A(H1N1)pdm09 and heterogenous results by country against A(H3N2).欧洲2013 - 2014年I - MOVE多中心病例对照研究。针对甲型(H1N1)pdm09流感病毒,流感疫苗有效性表现出一致性且处于中等水平;而针对甲型(H3N2)流感病毒,不同国家的研究结果存在差异。
Vaccine. 2015 Jun 4;33(24):2813-22. doi: 10.1016/j.vaccine.2015.04.012. Epub 2015 Apr 28.
8
Interim Estimates of 2017-18 Seasonal Influenza Vaccine Effectiveness - United States, February 2018.2017 - 18年季节性流感疫苗效力中期评估 - 美国,2018年2月
MMWR Morb Mortal Wkly Rep. 2018 Feb 16;67(6):180-185. doi: 10.15585/mmwr.mm6706a2.
9
Inactivated influenza vaccine effectiveness among department of defense beneficiaries aged 6 months-17 years, 2016-2017 through 2019-2020 influenza seasons.2016-2017 至 2019-2020 流感季节,6 个月至 17 岁国防部受益人群中灭活流感疫苗的有效性。
PLoS One. 2021 Aug 27;16(8):e0256165. doi: 10.1371/journal.pone.0256165. eCollection 2021.
10
Comparing influenza vaccine effectiveness between cell-derived and egg-derived vaccines, 2017-2018 influenza season.比较 2017-2018 流感季节细胞源性疫苗和鸡胚源性疫苗的流感疫苗效力。
Vaccine. 2019 Jul 9;37(30):4015-4021. doi: 10.1016/j.vaccine.2019.06.004. Epub 2019 Jun 11.

引用本文的文献

1
The Department of Defense Global Respiratory Pathogen Surveillance Program: its impact on public health, from the U.S. Armed Forces to global health.美国国防部全球呼吸道病原体监测计划:从美国武装部队到全球健康,其对公共卫生的影响
MSMR. 2025 Apr 20;32(4):32-40.
2
Using SARS-CoV-2 Sequencing Data to Identify Reinfection Cases in the Global Emerging Infections Surveillance Program, United States.利用 SARS-CoV-2 测序数据鉴定美国全球新发传染病监测计划中的再感染病例。
Emerg Infect Dis. 2024;30(14):53-61. doi: 10.3201/eid3014.240231.
3
Surveillance outcomes of respiratory pathogen infections during the 2021-2022 season among U.S. Military Health System beneficiaries, October 3, 2021-October 1, 2022.
2021-2022 年美国军人健康系统受种者呼吸道病原体感染的监测结果,2021 年 10 月 3 日-2022 年 10 月 1 日。
MSMR. 2024 May 20;31(5):16-23.
4
Influenza Vaccine Effectiveness Estimates among US Department of Defense Adult Beneficiaries over Four Consecutive Influenza Seasons: A Test-Negative Design Study with Different Control Groups.连续四个流感季节美国国防部成年受益人群中流感疫苗有效性评估:一项采用不同对照组的检测阴性设计研究
Vaccines (Basel). 2021 Dec 31;10(1):58. doi: 10.3390/vaccines10010058.
5
Inactivated influenza vaccine effectiveness among department of defense beneficiaries aged 6 months-17 years, 2016-2017 through 2019-2020 influenza seasons.2016-2017 至 2019-2020 流感季节,6 个月至 17 岁国防部受益人群中灭活流感疫苗的有效性。
PLoS One. 2021 Aug 27;16(8):e0256165. doi: 10.1371/journal.pone.0256165. eCollection 2021.